Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Few pooled analyses of antiresorptive (AR) treatment trials relate short-term changes in bone turnover markers (BTMs) to subsequent fracture reduction. Such information would be useful to assess new ARs or novel dosing regimens. In the Foundation for the National Institutes of Health (FNIH) Bone Quality project, we analyzed individual-level data from 28,000 participants enrolled in 11 bisphosphonate (BP) and three selective estrogen receptor modulator (SERM) placebo-controlled fracture endpoint trials. Using BTM results for two bone formation markers (bone-specific alkaline phosphatase [bone ALP] and pro-collagen I N-propeptide [PINP]) and two bone resorption markers (N-terminal and C-terminal telopeptide of type I collagen) and incident fracture outcome data, we performed a meta-regression relating the mean net effect of treatment on change in bone turnover (active minus placebo % difference after 3 to 12 months) to the log of study-wide fracture risk reduction, and used linear regression to plot the best fitting line. Separate analyses were performed for incident morphometric vertebral, nonvertebral, and hip fractures over 1 to 4 years of follow-up. Change in bone ALP and PINP were available for over 16,000 and 10,000 participants, respectively. For vertebral fracture, the results showed a strong relationship between treatment-related bone ALP or PINP changes and vertebral fracture risk reduction (r2 = 0.82 [p < 0.001] and r2 = 0.75 [p = 0.011], respectively) Relationships were weaker and no longer statistically significant for nonvertebral (r2 = 0.33 [p = 0.053] and r2 = 0.53 [p = 0.065], respectively) and hip fracture (r2 = 0.17 [p = 0.24] and r2 = 0.43 [p = 0.11], respectively) outcomes. Analyses limited to BP trials gave similar results. For all fracture types, relationships were weaker and nonsignificant for bone resorption markers. We conclude that short-term AR treatment-related changes in bone ALP and PINP strongly predict vertebral fracture treatment efficacy, but not nonvertebral or hip fracture treatment efficacy. Change in bone formation markers might be useful to predict the anti-vertebral fracture efficacy of new AR compounds or novel dosing regiments with approved AR drugs. © 2017 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986 · cited 2×
“Since 2002, additional large trials with other BPs (zoledronic acid,((12)) ibandronate((13))) and SERMS (bazedoxifene,((14)) lasofoxifene,((15)) and arzoxifene((16))) have been completed.”
BackgroundSelf-citationOsteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696 · cited 1×
“Unlike antiresorptive and anabolic therapies, formation sparing resorption inhibitors((20)) such as odanacatib result in a long-term decrease in bone resorption but not bone formation, and yet odanacatib treatment reduces the risk of both vertebral and nonvertebral fractures.”
Self-citationHarris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475 · cited 1×
“0 497/913/205 VERT-NORTH AMERICA (1999)((29)) Risedronate 1628 68.”
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationChesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Cited by
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
Self-citationBone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaca, T., Gossiel, F., Salam, S., & Eastell, R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 387
Self-citationChange in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Bouxsein, M. L., Eastell, R., Lui, L.-Y., Wu, L. A., de Papp, A. E., Grauer, A., Marin, F., Cauley, J. A., Bauer, D. C., Black, D. M., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3641 · Cited by 353
Self-citationRecent Progress in Space Physiology and Aging
Strollo, F., Gentile, S., Strollo, G., Mambro, A., & Vernikos, J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01551 · Cited by 85
“The reason for this depends on the fact that bone formation is coupled to bone resorption and therefore about one month after antiresorptive effects begin, a “frozen” bone remodeling condition occurs (Bauer et al., 2018).”
BackgroundStone, J. A., McCrea, J. B., Witter, R., Zajic, S., & Stoch, S. A. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13869 · Cited by 66
Metadata
- Authors
- Bauer, D. C., Black, D. M., Bouxsein, M. L., Lui, L.-Y., Cauley, J. A., de Papp, A. E., Grauer, A., Khosla, S., McCulloch, C. E., Eastell, R., & for the Foundation for the National Institutes of Health (FNIH) Bone Quality Project
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-10
- Volume
- 33
- Issue
- 4
- Pages
- 634-642
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2783185610
- Cited by
- 71
- References
- 11
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.